1. Amgen's Q1 2025 revenues increased 11% year-over-year to $8.15 billion. 2. Strong product demand and new launches drive confidence in long-term growth. 3. Free cash flow doubled to $1 billion, indicating solid financial health. 4. New product sales, such as Repatha and Tezspire, showed significant growth. 5. Operating margin improved to 15%, reflecting efficient cost management.
The strong revenue growth, product performance, and increasing operating margins indicate positive momentum for AMGN, historically correlating with favorable stock price movements post-earnings announcements.
The strong financial results are likely to foster investor enthusiasm, creating potential upward pressure on the stock due to improved perceptions of AMGN's market position.
Immediate market reactions to Q1 results will likely impact stock performance, as investor sentiment is influenced by quarterly data more than long-term projections.
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025.
"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects," said Robert A. Bradway, chairman and chief executive officer.
References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis," and "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented in the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion.
| $Millions, except percentages | Q1 '25 | Q1 '24 | YOY Δ | U.S | ROW | TOTAL |
|---|---|---|---|---|---|---|
| Repatha® | $ 343 | $ 313 | 27 % | $ 656 | ||
| EVENITY® | 320 | 122 | 29 % | 442 | ||
| Total product sales | $ 5,662 | $ 2,211 | 11 % | $ 7,873 | ||
Operating income as % of product sales: 15.0 %
$ 1.4 Billion
For the full year 2025, the Company expects:
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases...
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen...
Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)